Archives
-
ECL Western Blotting Substrate: Workflow Guide
2026-09-11
ECL Western Blotting Substrate (SKU K2187) is a luminol-based, nonradioactive reagent for detecting HRP-labeled proteins on immunoblots. It is intended for chemiluminescent Western blot assays recorded with X-ray film or CCD imaging, not for fluorescent or radioisotopic detection workflows.
-
Y-27632 Dihydrochloride for Organoid Workflows
2026-09-10
Y-27632 dihydrochloride gives researchers a controlled way to test how ROCK signaling influences hEPSC survival, cytoskeletal remodeling, and cartilaginous organoid maturation. This practical guide adapts the 2025 hEPSC cartilage protocol into a staged ROCK-inhibitor workflow while separating validated findings from optimization hypotheses.
-
EPZ5676: Translational Precision in DOT1L Inhibition
2026-09-10
EPZ5676 illustrates how a highly selective DOT1L inhibitor can connect biochemical precision with MLL-rearranged leukemia research and emerging fibrosis biology. This thought-leadership analysis outlines the mechanistic rationale, experimental workflow, translational opportunities, and limitations that should guide next-generation H3K79 methylation studies.
-
Cy3 Goat Anti-Human IgG (H+L) Antibody: Lab Scenarios
2026-09-09
This scenario-based guide shows how Cy3 Goat Anti-Human IgG (H+L) Antibody, SKU K1208, can strengthen human IgG detection alongside cell viability, proliferation, and cytotoxicity workflows. It covers assay compatibility, handling, interpretation, cross-domain limitations, and practical vendor-selection criteria.
-
AAL-993: A VEGF Receptor Inhibitor Workflow
2026-09-09
AAL-993 enables target-focused investigation of VEGFR-1, VEGFR-2, and VEGFR-3 across biochemical, endothelial, and tumor-model workflows. Its defined kinase selectivity makes it a practical complement to network-pharmacology studies that identify broader signaling programs in cancer biology.
-
Isoproterenol Sulfate Dihydrate in SAN Assays
2026-09-08
Use Isoproterenol sulfate dihydrate to impose a defined beta-adrenergic challenge on human PSC-derived sinoatrial node and cardiac plexus models. Its acute cAMP/PKA response complements, rather than replaces, the slower neuro-pacemaker maturation captured by SAN-plexus assembloids.
-
JXY, TLR4, and M1 Polarization in Colitis-Associated CRC
2026-09-08
The reference study shows that Jiedu Xiaozheng Yin suppresses colitis-associated colorectal cancer in mice while shifting intestinal macrophages toward an M1-like phenotype through TLR4-associated signaling. Its combined in vivo, cell-based, gene-expression, flow-cytometry, and pharmacological-inhibition design provides a useful framework for linking tumor-microenvironment remodeling with disease control.
-
Cy5-UTP RNA Labeling: Workflow & Troubleshooting
2026-09-07
Cy5-UTP enables direct, far-red visualization of RNA made by T7 in vitro transcription, supporting FISH, multicolor assays, and RNA probe synthesis without a secondary staining step. This guide connects practical labeling optimization with circRNA vaccine quality-control questions raised by a recent hepatocellular carcinoma study.
-
NAD+ Protects Hepatocytes from Palmitate Lipotoxicity
2026-09-07
A 2025 study identifies a PARP-1–mTORC1–p300 pathway that links palmitate exposure to hepatocyte injury and shows that preserving cellular NAD+ can interrupt this process. The findings provide a mechanistic framework for testing NAD+-raising, NNMT-inhibitory, PARG-inhibitory, and p300-targeted strategies in metabolic liver disease models.
-
Thermal Shift Assays for Bacterial Sensor Ligands
2026-09-05
Monteagudo-Cascales and colleagues review how thermal shift assays identify ligands for bacterial receptors, solute-binding proteins, and transcriptional regulators when their signals are unknown. The paper’s main practical contribution is a rigorous workflow that combines ligand-binding domains, pH optimization, careful interpretation of thermal shifts, and orthogonal validation such as isothermal titration calorimetry.
-
Vemurafenib (PLX4032) Melanoma Workflows
2026-09-04
Build mutation-matched melanoma assays with Vemurafenib (PLX4032), from concentration-response profiling to early MAPK signaling and resistance analysis. The workflow connects BRAF V600E-dependent proliferation with ARID1A-associated adaptive rewiring, making it useful for cancer biology and metastatic melanoma research.
-
Dinaciclib (SCH727965) in Boundary-Aware Cancer Research
2026-09-04
Dinaciclib (SCH727965) connects CDK-driven proliferation with Rb phosphorylation, cell-cycle disruption, and apoptosis readouts. This workflow shows how to use the compound in cancer research while adapting tissue-boundary concepts from Drosophila developmental biophysics to more rigorous live-cell and mechanistic assays.
-
mRNA Pyroptosis Sensitizes Cold Tumors to Immunotherapy
2026-09-03
The Nature Communications study develops an mRNA lipid nanoparticle system that directly expresses the pore-forming N-terminal domain of gasdermin B, inducing pyroptosis without relying on endogenous proteolytic cleavage. In mouse tumor models, this approach increased inflammatory immune activity, converted immunologically cold tumors into more T-cell-infiltrated lesions, and improved responses to anti-PD-1 therapy, including effects at distant tumor sites.
-
FITC-Concanavalin A (ConA) Conjugate Guide
2026-09-03
FITC-Concanavalin A is a fluorescent lectin conjugate for detecting accessible α-D-glucose and α-D-mannose residues on glycoproteins and glycolipids in cell, tissue, and flow-based assays. It is not a universal glycan stain, general protein label, or suitable probe for non-carbohydrate targets, so controls and buffer compatibility must be established during assay development.
-
Pseudo-UTP: From RNA Chemistry to Translation Strategy
2026-09-02
A translational framework for using Pseudo-UTP in RNA engineering, linking pseudouridine chemistry with UTR optimization, experimental controls, and decision-making for mRNA vaccine development and gene therapy research.